NLRP3 inflammasome activation from Kupffer cells is involved in liver fibrosis of Schistosoma japonicum-infected mice via NF-κB

Abstract

BackgroundNOD-like receptor protein 3 (NLRP3) inflammasome was reported as expressed in schistosomiasis-induced liver fibrosis (SSLF). We used an NLRP3 inflammasome inhibitor, MCC950, to investigate whether it inhibited liver fibrosis, and explored the preliminary molecular mechanism.MethodsBALB/c mice were infected with 15 cercariae through the abdominal skin. They received intraperitoneal injections of MCC950 on the day of infection and at day 22 post-infection. We examined their SSLF phenotype and the effect on liver fibrosis, primary Kupffer cells (KCs), and HSCs. Human hepatic stellate cell lines (human LX-2 cells) were treated with soluble egg antigen (SEA) released from the eggs. We then determined the expression of NLRP3 inflammasome and liver fibrosis-associated markers, liver granuloma and ALT/AST.ResultsNLRP3 inflammasome expression in the liver was significantly increased, and eosinophilic granuloma and collagen deposition were found around the eggs in mice infected for 56 days. Additionally, IL-1β, ALT/AST in plasma, and NF-κB in liver tissue and in KCs were all greatly significantly increased. The above-mentioned indicators were largely reduced in mice treated with MCC950 on the day of infection. In vitro, lipopolysaccharide (LPS)/SEA could induce LX-2 cells to express NLRP3 and fibrosis markers, and the SEA-treated group was reversed by MCC950. Furthermore, NLRP3 inflammasome and liver fibrosis-associated markers were both increased in the primary KCs and HSCs isolated from infected mice. However, this effect was not observed in the same cells from the mice treated with MCC950 on the day of infection. Contrary to the aforementioned results, MCC950 treatment at day 22 post-infection aggravated this process. Surprisingly, NLRP3 inflammasome was involved in liver fibrosis mostly from KCs.ConclusionsMCC950 acts dually on SSLF pathology and fibrosis in infected mice. Although MCC950 treatment improved SSLF on the day of infection, it exacerbated the pathological effects at day 22 post-infection. These dual effects were mediated via NF-κB. Moreover, NLRP3 inflammasome mainly came from KCs. Our results suggest that blocking NLRP3 on the day of infection may prove to be a promising direction in preventing SSLF.

Scutellarin ameliorates pulmonary fibrosis through inhibiting NF-κB/NLRP3-mediated epithelial–mesenchymal transition and inflammation

“…Previous studies demonstrated that NF-κB/NLRP3 signaling pathway promoted liver fibrosis in mice 29 . Thus, we wanted to explore if the activation of NF-κB/NLRP3 signaling was involved in pulmonary fibrosis and if scutellarin regulated this pathway.…”

Methane-Rich Saline Counteracts Cholestasis-Induced Liver Damage via Regulating the TLR4/NF-κB/NLRP3 Inflammasome Pathway

“…The activation of NF- κ B upregulates the expression of NLRP3 protein, which subsequently promotes more production of IL-1 β and eventually leads to pyroptosis [17]. NLRP3 inflammasome activation is correlated with liver fibrosis during BDL [18].…”

Mechanism of TGF‑β1 inhibiting Kupffer cell immune responses in cholestatic cirrhosis

“…KCs is mainly grouped into two significantly different types: classically activated M1 KCs and alternatively activated M2 KCs. iNOS is recognized in considerable number of studies as a specific expression marker of M1 macrophages, whereas, Found in Inflammatory Zone 1 (FIZZ1), arginase-1 (Arg-1) and IL-10 are those of M2 macrophages (51,52). In both the animal trial and cell trial, TGF-β1 treatment was observed to elevate the expression of M2-specific ARG-1 and the percentages of surface antigens CD203 and CD206, but lower the expression of M1-specific iNOS and the percentages of CD40 and CD86, which indicated that TGF-β1 treatment could induce M2 transformation of macrophages in cholestatic mice.…”